Figure 1. IL-12 is required in antitumor function of CpG.

Tumor cells were subcutaneously injected into WT-B6 (A. B16-OVA; C. E0771) and IL-12-deficient (KO) (B. B16-OVA; D. E0771) mice. On day 7 after tumor injection, CpG, Poly I:C, or control (carrier PBS) were injected into tumor tissues (i.t.) daily for three doses. Data show mean ± s.e.m. of 5 mice per group of WT mice and IL-12 KO mice. **P< 0.01 between control and CpG or Poly I:C groups (Two-way ANOVA).